Abstract:Background: Protein phosphotylation is one of the essential steps in cell signaling, and aberrant phosphorylation is a common event in human cancer. The expression of receptor type protein tyrosine phosphatase gamma (PTPRG) in normal breast is found to be similar to 50-60% higher than that of breast tumor tissue. Overexpression of PTPRG inhibits anchorage-independent growth and proliferation of breast cancer cells. To understand the tumor suppression characteristics of PTPRG, we studied its tumor suppressive function in an athymic mouse model and evaluated factors that can potentially regulate its expression in breast cancer cells. Materials and Methods: To investigate the function of PTPRG in vivo, athymic nude mice were implanted with MCF-7 cells overexpressing PTPRG. For in vitro study, protein levels of cell cycle regulators, cell cycle re-entry, and the phosphorylation levels of extracellular signal-regulated protein kinases 112 (ERKI/2) were examined. In addition, methylation assays were conducted to investigate the epigenetic modification on the promoter of PTPRG. Results: Athymic nude mice bearing MCF-7 cells overexpressing PTPRG showed a reduction in tumor burden in comparison to animals implanted with MCF-7 cells transfected with vector alone. When these two cell lines were studied in an in vitro system, elevated mRNA and protein levels of cell cycle regulators, p21(cip) and p27(kip) were detected in MCF-7 cells overexpressing PTPRG compared to cells transfected with vector alone. Similarly, overexpression of PTPRG also delayed the re-entry of breast cancer cells into the cell cycle after serum starvation, and reduced the phosphorylation levels ERK1/2 in MCF-7 cells. In addition, methylation assays in PTPRG promoter in breast cancer cell lines (including SK-Br-3) revealed an aberrant methylation pattern. When SK-Br-3 and MCF-7 cells were treated with deoxy-5-azacytidine (DAC) and trichostatin A (TSA), these compounds reactivated the expression of PTPRG, suggesting an epigenetic control on its expression. Conclusion: Our results indicated that PTPRG inhibited breast tumor formation in vivo; PTPRG may up-regulate p21(cip) and p27(kip) proteins through the ERK1/2 pathway. This study also showed methylation-mediated silencing of PTPRG in breast cancer cell lines. These data indicate that PTPRG exhibits the characteristics of a breast tumor suppressor.

PTPRO Represses ERBB2-driven Breast Oncogenesis by Dephosphorylation and Endosomal Internalization of ERBB2

Tyrosine Phosphatase PTPRO Deficiency in ERBB2-Positive Breast Cancer Contributes to Poor Prognosis and Lapatinib Resistance

DEPTOR Stabilizes ErbB2 to Promote the Proliferation and Survival of ErbB2-positive Breast Cancer Cells.

Protein Tyrosine Phosphatase Receptor Type O Expression in the Tumor Niche Correlates with Reduced Tumor Growth, Angiogenesis, Circulating Tumor Cells and Metastasis of Breast Cancer

PTPRO represses colorectal cancer tumorigenesis and progression by reprogramming fatty acid metabolism

Function and Regulatory Mechanisms of the Candidate Tumor Suppressor Receptor Protein Tyrosine Phosphatase Gamma (PTPRG) in Breast Cancer Cells.

PTPRO suppresses lymph node metastasis of esophageal carcinoma by dephosphorylating MET

Tumor-Derived Exosomal Protein Tyrosine Phosphatase Receptor Type O Polarizes Macrophage to Suppress Breast Tumor Cell Invasion and Migration

PTPRO is a Therapeutic Target and Correlated with Immune Infiltrates in Pancreatic Cancer.

Protein tyrosine phosphatase PTPRO represses lung adenocarcinoma progression by inducing mitochondria-dependent apoptosis and restraining tumor metastasis

PTPRO Promoter Methylation is Predictive of Poorer Outcome for HER2-positive Breast Cancer: Indication for Personalized Therapy.

Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3.

TRPS1 Regulates the Opposite Effect of Progesterone Via RANKL in Endometrial Carcinoma and Breast Carcinoma

Nuclear ErbB2 Represses DEPTOR Transcription to Inhibit Autophagy in Breast Cancer Cells

Protein Tyrosine Phosphatase Receptor-Type Δ Acts As a Negative Regulator Suppressing Breast Cancer

Role of Protein Tyrosine Phosphatase Receptor Type E (PTPRE) in Chemoresistant Retinoblastoma

PTPRO-related CD8(+) T-cell signatures predict prognosis and immunotherapy response in patients with breast cancer

PTPROt Maintains T Cell Immunity in the Microenvironment of Hepatocellular Carcinoma.

Protein Tyrosine Phosphatase Μ (PTP Μ or PTPRM), a Negative Regulator of Proliferation and Invasion of Breast Cancer Cells, is Associated with Disease Prognosis.

PTPRB promotes metastasis of colorectal carcinoma via inducing epithelial-mesenchymal transition

Effect of PTPRB on Metastasis of Colorectal Carcinoma and Induction of Epithelial-Mesenchymal Transition.